Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury.
Hepatotoxicity
Herbal and Dietary Supplement
Weight Loss Supplement
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
20
04
2021
revised:
05
08
2021
accepted:
09
08
2021
pubmed:
18
8
2021
medline:
10
5
2022
entrez:
17
8
2021
Statut:
ppublish
Résumé
Garcinia cambogia, either alone or with green tea, is commonly promoted for weight loss. Sporadic cases of liver failure from G cambogia have been reported, but its role in liver injury is controversial. Among 1418 patients enrolled in the Drug-Induced Liver Injury Network (DILIN) from 2004 to 2018, we identified 22 cases (adjudicated with high confidence) of liver injury from G cambogia either alone (n = 5) or in combination with green tea (n = 16) or Ashwagandha (n = 1). Control groups consisted of 57 patients with liver injury from herbal and dietary supplements (HDS) containing green tea without G cambogia and 103 patients from other HDS. Patients who took G cambogia were between 17 and 54 years, with liver injury arising 13-223 days (median = 51) after the start. One patient died, one required liver transplantation, and 91% were hospitalized. The liver injury was hepatocellular with jaundice. Although the peak values of aminotransferases were significantly higher (2001 ± 1386 U/L) in G cambogia group (P < .018), the median time for improvement in total bilirubin was significantly lower compared with the control groups (10 vs 17 and 13 days; P = .03). The presence of HLA-B∗35:01 allele was significantly higher in the G cambogia containing HDS (55%) compared with patients because of other HDS (19%) (P = .002) and those with acute liver injury from conventional drugs (12%) (P = 2.55 × 10 The liver injury caused by G cambogia and green tea is clinically indistinguishable. The possible association with HLA-B∗35:01 allele suggests an immune-mediated mechanism of injury. gov number: NCT00345930.
Sections du résumé
BACKGROUND & AIMS
Garcinia cambogia, either alone or with green tea, is commonly promoted for weight loss. Sporadic cases of liver failure from G cambogia have been reported, but its role in liver injury is controversial.
METHODS
Among 1418 patients enrolled in the Drug-Induced Liver Injury Network (DILIN) from 2004 to 2018, we identified 22 cases (adjudicated with high confidence) of liver injury from G cambogia either alone (n = 5) or in combination with green tea (n = 16) or Ashwagandha (n = 1). Control groups consisted of 57 patients with liver injury from herbal and dietary supplements (HDS) containing green tea without G cambogia and 103 patients from other HDS.
RESULTS
Patients who took G cambogia were between 17 and 54 years, with liver injury arising 13-223 days (median = 51) after the start. One patient died, one required liver transplantation, and 91% were hospitalized. The liver injury was hepatocellular with jaundice. Although the peak values of aminotransferases were significantly higher (2001 ± 1386 U/L) in G cambogia group (P < .018), the median time for improvement in total bilirubin was significantly lower compared with the control groups (10 vs 17 and 13 days; P = .03). The presence of HLA-B∗35:01 allele was significantly higher in the G cambogia containing HDS (55%) compared with patients because of other HDS (19%) (P = .002) and those with acute liver injury from conventional drugs (12%) (P = 2.55 × 10
CONCLUSIONS
The liver injury caused by G cambogia and green tea is clinically indistinguishable. The possible association with HLA-B∗35:01 allele suggests an immune-mediated mechanism of injury.
CLINICAL TRIALS
gov number: NCT00345930.
Identifiants
pubmed: 34400337
pii: S1542-3565(21)00871-5
doi: 10.1016/j.cgh.2021.08.015
pmc: PMC9004424
mid: NIHMS1792452
pii:
doi:
Substances chimiques
HLA-B Antigens
0
Tea
0
Banques de données
ClinicalTrials.gov
['NCT00345930']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1416-e1425Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK065211
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK065176
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK083027
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK083020
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK065238
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK065193
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM130457
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK065176
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK083023
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK065184
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK082992
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK065201
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK100928
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Références
World J Mens Health. 2021 Apr;39(2):208-221
pubmed: 32202085
Gastroenterology. 2015 Jun;148(7):1340-52.e7
pubmed: 25754159
Int J Mol Sci. 2016 Apr 09;17(4):537
pubmed: 27070596
Patient Educ Couns. 2017 Mar;100(3):592-597
pubmed: 27847132
J Med. 2004;35(1-6):33-48
pubmed: 18084863
Eur J Med Res. 2006 Aug 30;11(8):343-50
pubmed: 17052970
Clin Gastroenterol Hepatol. 2022 Mar;20(3):e548-e563
pubmed: 33434654
Physiol Behav. 2000 Oct 1-15;71(1-2):87-94
pubmed: 11134690
Phytother Res. 2020 Mar;34(3):526-545
pubmed: 31793087
Mol Cell Biochem. 2002 Sep;238(1-2):89-103
pubmed: 12349913
Complement Ther Med. 2013 Aug;21(4):407-16
pubmed: 23876572
World J Hepatol. 2019 Nov 27;11(11):735-742
pubmed: 31772720
Food Chem Toxicol. 2005 Nov;43(11):1683-4; author reply 1685-6
pubmed: 15993998
Am J Health Promot. 2014 Jul-Aug;28(6):364-71
pubmed: 24977497
Nature. 2019 May;569(7755):260-264
pubmed: 31068725
Intern Emerg Med. 2018 Sep;13(6):857-872
pubmed: 29802521
Ann Hepatol. 2016 Jan-Feb;15(1):123-6
pubmed: 26626648
Hepatology. 2021 Jun;73(6):2484-2493
pubmed: 32892374
JAMA. 1998 Nov 11;280(18):1596-600
pubmed: 9820262
Gastroenterology. 2015 Mar;148(3):480-2
pubmed: 25579757
Heart Rhythm. 2009 May;6(5):663-4
pubmed: 19328043
Case Reports Hepatol. 2018 Mar 12;2018:6483605
pubmed: 29721342
Case Rep Gastrointest Med. 2018 Jul 26;2018:9606171
pubmed: 30147968
Nutrients. 2021 Jan 29;13(2):
pubmed: 33572973
J Agric Food Chem. 2002 Jan 2;50(1):10-22
pubmed: 11754536
Curr Ther Res Clin Exp. 2003 Sep;64(8):551-67
pubmed: 24944404
Obesity (Silver Spring). 2008 Apr;16(4):790-6
pubmed: 18239570
Hepatology. 2014 Oct;60(4):1399-408
pubmed: 25043597
Hepatology. 2019 Jul;70(1):346-357
pubmed: 30985007
Stud Health Technol Inform. 2019 Aug 21;264:323-327
pubmed: 31437938
Hepatol Commun. 2019 Apr 03;3(6):792-794
pubmed: 31168513
World J Gastroenterol. 2013 Aug 7;19(29):4689-701
pubmed: 23922466
ACG Case Rep J. 2020 Aug 11;7(8):e00429
pubmed: 32821764
Perm J. 2018;22:17-082
pubmed: 29401050
Obes Surg. 2021 Mar;31(3):1105-1112
pubmed: 32986169